St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
NCT Number: NCT00667927
This study proposes to transfer marker genes (detectable genetic traits or segments of DNA that can be identified and tracked) into aliquots of marrow obtained for Bone Marrow Transplant (BTM) in patients in remission of Acute Myelogenous Leukemia (AML).
Looking for future studies?
Notify Me1 year–18 year
All sexes
Interventional
Phase 1
Memphis, Tennessee, 38105, United States
The primary objective of this study was to estimate the continuous complete remission rate at 2 years post transplant for children with AML in first complete remission treated with autologous BMT.
Secondary objectives used transduction of marker genes into autologous marrow to determine the following:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
See Detailed Description section for description of treatment plan.
Other names: Myleran
See Detailed Description section for description of treatment plan.
Other names: Cytoxan, CTX
See Detailed Description section for description of treatment plan.
Other names: MESNCX
Time frame: 2 years post transplant
St. Jude Children's Research Hospital
Other
Autologous Bone Marrow Transplant for Children With AML in First Complete Remission: Use of Marker Genes to Investigate the Biology of Marrow Reconstitution and the Mechanism of Relapse
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03573024
Acute Myeloid Leukemia, Hematologic Diseases
Aurora, Colorado, United States
View Trial DetailsNCT06006403
Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm
Taiyuan, Shanxi, China
View Trial DetailsNCT02971397
Acute Myeloid Leukemia, Hematologic Diseases
Winston-Salem, North Carolina, United States
View Trial DetailsNCT03836209
Acute Myeloid Leukemia, Hematologic Diseases
Scottsdale, Arizona, United States
View Trial Details